P/E at 38.29 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd

1 hour ago

Share Via

A price-to-earnings ratio of 38.29 against an industry average of 37.19 reveals a modest premium for Sun Pharmaceutical Industries Ltd. Previously rated Hold by MarketsMojo, the company’s rating was reassessed on 8 June 2026. While the one-year return of 20.50% comfortably outpaces the Sensex’s -2.37%, the stock’s recent short-term performance shows signs of pressure, with a 1-day decline of -1.33% and a 1-week drop of -0.53%. The data paints a nuanced picture of valuation and momentum across timeframes.

Valuation Picture: Premium Amidst Sector Parity

Sun Pharmaceutical Industries Ltd trades at a P/E of 38.29, slightly above the Pharmaceuticals & Biotechnology industry average of 37.19. This premium, though not extreme, suggests investors are willing to pay a bit more for the company’s earnings relative to its peers. The market capitalisation stands at a substantial ₹4,70,977.46 crores, underscoring its large-cap stature within the sector. Such a valuation premium often reflects expectations of superior earnings growth or stability, but it also raises questions about whether the premium is justified given recent performance trends — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Strong Medium-Term Gains Tempered by Recent Weakness

The stock’s performance over the past year has been robust, delivering a 20.50% gain compared to the Sensex’s decline of -2.37%. This outperformance extends to longer horizons as well, with 3-year and 5-year returns of 72.06% and 146.96% respectively, both significantly ahead of the Sensex’s 20.61% and 46.20%. However, the short-term momentum is less encouraging. The 1-day and 1-week returns are negative at -1.33% and -0.53%, respectively, while the 1-month and 3-month returns remain positive but more modest at 3.06% and 8.56%. This divergence suggests that while the stock has enjoyed sustained gains over the medium term, recent market dynamics have introduced some volatility — is this a temporary correction or a sign of shifting fundamentals?

Moving Average Configuration: Bullish Across All Key Averages

Technically, Sun Pharmaceutical Industries Ltd is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning above short, medium, and long-term averages indicates a strong underlying trend and suggests that despite recent daily losses, the stock remains in a technically bullish phase. The proximity to its 52-week high, just 2.93% away, further supports this view. The 1-day underperformance relative to the sector by -1.05% may be a short-term fluctuation rather than a trend reversal — is this a genuine recovery or a dead-cat bounce? — the moving average configuration provides the clearest answer.

Sector Context: Mixed Results Amidst Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently, with 10 stocks declaring results: 5 positive, 4 flat, and 1 negative. This distribution indicates a sector grappling with varied performance drivers, from regulatory challenges to innovation cycles. Within this environment, Sun Pharmaceutical Industries Ltd stands out with its consistent medium-term outperformance, though the recent short-term softness aligns with some sector peers’ flat or negative results. The sector’s average P/E of 37.19 provides a useful benchmark for valuation comparisons, reinforcing the modest premium at which Sun Pharma trades.

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd, with a Mojo Score of 72.0. The rating was updated on 8 June 2026, reflecting the evolving data landscape. This reassessment takes into account the company’s valuation premium, sustained medium-term performance, and technical positioning. The question remains — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Collective Data Insights: Valuation, Momentum, and Technicals in Balance

Bringing together the valuation, performance, and technical data, Sun Pharmaceutical Industries Ltd presents a compelling case of a large-cap stock trading at a slight premium to its sector, supported by strong medium-term returns and a bullish moving average configuration. The recent short-term underperformance and daily losses highlight the importance of monitoring momentum shifts closely. The sector’s mixed results add further nuance, suggesting that while the company remains a leader in its space, it is not immune to broader industry headwinds. The updated rating from previously Hold reflects these complexities — what is the current rating and how should investors interpret it?

Summary

In summary, Sun Pharmaceutical Industries Ltd is positioned with a valuation premium that is modest but notable, backed by strong multi-year returns and a technical setup that remains bullish across all major moving averages. The short-term volatility and sector-wide mixed results warrant attention, but the overall data suggests a stock that has delivered consistent value over time. Investors should weigh these factors carefully in light of the recent rating reassessment and evolving market conditions.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE